CJC-1295 (without DAC) and Semaglutide Interaction

Monitor
Mechanism-based 47% confidence

CJC-1295 (without DAC) and Semaglutide have an interaction requiring monitoring for interaction with 47% confidence. Both CJC-1295 (without DAC) and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Both compounds affect the gi tract, so monitoring these systems is recommended.

Compound Profiles

CJC-1295 (without DAC)

Short-Acting Growth Hormone Releasing Hormone Analog

Binds GHRH receptors on somatotroph cells in the pituitary gland, stimulating cAMP production and physiological GH pulses. The brief 30-minute half-life allows pulsatile release versus prolonged elevation.

Half-life: 30 minutes - 2 hours Typical dose: 100-300mcg per injection growth hormone, weight loss
ghrh receptor carcinogenic riskestrogenicinsulin disruptingteratogenic
View full profile

Semaglutide

GLP-1 Receptor Agonist | Weight Loss & Diabetes

Mimics native GLP-1, binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways..

Half-life: ~7 days (168 hours) Typical dose: 0.25mg starting, titrate to 1-2.4mg weekly weight loss, metabolic
glp1 receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pituitary
low
Pancreas
low

Shared Safety Flags

2x 2 compounds share the carcinogenic-risk safety flag (CJC-1295 (without DAC), Semaglutide). Monitor accordingly.
2x 2 compounds affect insulin sensitivity (CJC-1295 (without DAC), Semaglutide). Monitor fasting glucose and HbA1c.
2x 2 compounds share the teratogenic safety flag (CJC-1295 (without DAC), Semaglutide). Monitor accordingly.

Frequently Asked Questions

Can I take CJC-1295 (without DAC) with Semaglutide?

Yes, but with caution. Both CJC-1295 (without DAC) and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). Regular monitoring is advised.

Is CJC-1295 (without DAC) and Semaglutide safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: carcinogenic risk, insulin disrupting, teratogenic. Monitor accordingly.

What are the interactions between CJC-1295 (without DAC) and Semaglutide?

Both CJC-1295 (without DAC) and Semaglutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine). This assessment has 47% confidence and is inferred from pharmacological mechanism analysis.

How should I time CJC-1295 (without DAC) and Semaglutide?

CJC-1295 (without DAC) has a half-life of 30 minutes - 2 hours and Semaglutide has a half-life of ~7 days (168 hours). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: CJC-1295 (without DAC) vs Semaglutide

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.